AU2016337370A1 - Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C - Google Patents

Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C Download PDF

Info

Publication number
AU2016337370A1
AU2016337370A1 AU2016337370A AU2016337370A AU2016337370A1 AU 2016337370 A1 AU2016337370 A1 AU 2016337370A1 AU 2016337370 A AU2016337370 A AU 2016337370A AU 2016337370 A AU2016337370 A AU 2016337370A AU 2016337370 A1 AU2016337370 A1 AU 2016337370A1
Authority
AU
Australia
Prior art keywords
mitomycin
liposomes
doxorubicin
prodrug
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016337370A
Other languages
English (en)
Inventor
Alberto Gabizon
Patricia OHANA
Hilary Shmeeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipomedix Pharmaceuticals Ltd
Shaare Zedek Scientific Ltd
Original Assignee
Lipomedix Pharmaceuticals Ltd
Shaare Zedek Scientific Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipomedix Pharmaceuticals Ltd, Shaare Zedek Scientific Ltd filed Critical Lipomedix Pharmaceuticals Ltd
Publication of AU2016337370A1 publication Critical patent/AU2016337370A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016337370A 2015-10-15 2016-10-14 Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C Abandoned AU2016337370A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242097P 2015-10-15 2015-10-15
US62/242,097 2015-10-15
PCT/US2016/057176 WO2017066667A1 (en) 2015-10-15 2016-10-14 Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c

Publications (1)

Publication Number Publication Date
AU2016337370A1 true AU2016337370A1 (en) 2018-05-17

Family

ID=57209906

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016337370A Abandoned AU2016337370A1 (en) 2015-10-15 2016-10-14 Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C

Country Status (6)

Country Link
US (1) US10617672B2 (enExample)
EP (1) EP3362099A1 (enExample)
JP (1) JP2018530623A (enExample)
AU (1) AU2016337370A1 (enExample)
CA (1) CA3001699A1 (enExample)
WO (1) WO2017066667A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066667A1 (en) 2015-10-15 2017-04-20 Lipomedix Pharmaceuticals Ltd. Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c
WO2020058372A1 (en) * 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
CN109260155B (zh) * 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
US12171746B2 (en) 2019-01-11 2024-12-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
WO2021225113A1 (ja) * 2020-05-08 2021-11-11 国立大学法人京都工芸繊維大学 イオン性化学種濃縮方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US20050129753A1 (en) * 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
EP2531175A2 (en) 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
EP2731591B1 (en) * 2011-07-13 2020-06-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
JP2014523444A (ja) * 2011-07-19 2014-09-11 エスティーシー． ユーエヌエム 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体
US9849087B2 (en) * 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
CN103622912B (zh) * 2013-12-05 2016-02-24 常州金远药业制造有限公司 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法
WO2015191576A1 (en) * 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
WO2017066667A1 (en) 2015-10-15 2017-04-20 Lipomedix Pharmaceuticals Ltd. Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c

Also Published As

Publication number Publication date
US10617672B2 (en) 2020-04-14
WO2017066667A1 (en) 2017-04-20
US20180296529A1 (en) 2018-10-18
CA3001699A1 (en) 2017-04-20
JP2018530623A (ja) 2018-10-18
EP3362099A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
EP3787607B1 (en) Carotenoid compositions and uses thereof
JP5419716B2 (ja) オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
US10617672B2 (en) Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
RS20080388A (sr) Lečenje malignih bolesti
Marzban et al. Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies
WO2014101356A1 (zh) 一种蟾毒灵脂质体及其制备方法和应用
CN115605196A (zh) 用于治疗癌症和癌症耐药性的脂质体制剂
CN116635009A (zh) 用于递送抗癌剂的具有改进的治疗指数的组合物和方法
US20240173257A1 (en) Liposome formulations
CN107530283A (zh) 组合脂质体药物制剂
EP3861987A1 (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
JP7842015B2 (ja) リポソームアナマイシンによる肺標的抗癌療法
WO2015191563A1 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin c
US20250064784A1 (en) Liposome composition comprising liposomal prodrug of mitomycin c and methods of treatment
CN114746124A (zh) 包含活性剂沉淀物的递送系统复合物和使用方法
US20220296518A1 (en) Lipid-based nanoparticle delivery system for hydrophilic charged compound
KR20100031320A (ko) 혈류 내 순환시간 증가를 위한 단백질로 결합된 리포솜 및 이의 제조방법
WO2025184543A1 (en) Compositions and methods for delivery of therapeutic compounds
HK40086650A (zh) 用於治疗癌症和癌症耐药性的脂质体制剂
EA051237B1 (ru) Липосомные составы
CN120225196A (zh) 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物
HK40084394A (en) Ethanolamine formulation for treating epithelial ovarian carcinoma
CN116407548A (zh) 一种蒽环类抗肿瘤药和铂类抗肿瘤药的组合物及其制备方法
KR20110122682A (ko) 콜레스탄올 유도체의 병용 용도
Lewi et al. Liposomal drug carriers

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application